TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $58.60.
TGTX has been the topic of a number of research analyst reports. Weiss Ratings raised TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of TG Therapeutics in a research note on Wednesday, May 27th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a research note on Monday.
Read Our Latest Stock Report on TGTX
Institutional Trading of TG Therapeutics
TG Therapeutics Stock Up 0.1%
Shares of TGTX opened at $53.63 on Friday. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. TG Therapeutics has a 12 month low of $25.28 and a 12 month high of $57.38. The stock’s 50 day moving average is $41.77 and its two-hundred day moving average is $34.42. The firm has a market cap of $8.21 billion, a P/E ratio of 18.75 and a beta of 1.68.
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The business had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. During the same period in the previous year, the business posted $0.03 earnings per share. The firm’s revenue for the quarter was up 69.5% on a year-over-year basis. Analysts predict that TG Therapeutics will post 1.51 earnings per share for the current fiscal year.
TG Therapeutics Company Profile
TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.
In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.
Read More
- Five stocks we like better than TG Therapeutics
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
